| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0272-6386(95)90120-5 |
| P698 | PubMed publication ID | 7702047 |
| P2093 | author name string | M M Schwartz | |
| S M Korbet | |||
| R Z Borok | |||
| J J Rydel | |||
| P433 | issue | 4 | |
| P921 | main subject | glomerulosclerosis | Q5571239 |
| P304 | page(s) | 534-542 | |
| P577 | publication date | 1995-04-01 | |
| P1433 | published in | American Journal of Kidney Diseases | Q4744250 |
| P1476 | title | Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment | |
| P478 | volume | 25 |
| Q73071359 | A 19-year-old man with hypertension, proteinuria, and renal insufficiency |
| Q47155702 | A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis |
| Q37280842 | A patient with nephrotic-range proteinuria and focal global glomerulosclerosis |
| Q33688313 | Angiotensin-converting enzyme gene polymophism in adult primary focal segmental glomerulosclerosis |
| Q38805701 | Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults. |
| Q30235177 | Calcineurin Inhibitors in the Treatment of Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis of the Literature |
| Q73071319 | Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? |
| Q73881245 | Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997 |
| Q39535922 | Changing incidence of glomerular diseases in adults |
| Q87393373 | Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults |
| Q38017937 | Childhood nephrotic syndrome--current and future therapies |
| Q34499836 | Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants |
| Q36199569 | Clinical outcomes and predictors for ESRD and mortality in primary GN. |
| Q35837532 | Clinical trial of focal segmental glomerulosclerosis in children and young adults |
| Q30427819 | Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life |
| Q37241092 | Clinicopathological correlation and treatment response of primary focal segmental glomerulosclerosis in adults and adolescents |
| Q46291457 | Complete remission of nephrotic syndrome in an infant with focal segmental glomerulosclerosis: is it renin-angiotensin blockade? |
| Q47108714 | Determination of the optimal target level of proteinuria in the management of patients with glomerular diseases by using different definitions of proteinuria |
| Q92074420 | Dextran-Sulfate Plasma Adsorption Lipoprotein Apheresis in Drug Resistant Primary Focal Segmental Glomerulosclerosis Patients: Results From a Prospective, Multicenter, Single-Arm Intervention Study |
| Q36161793 | Diagnosing FSGS without kidney biopsy - a novel INF2-mutation in a family with ESRD of unknown origin |
| Q42146267 | Early focal segmental glomerulosclerosis as a cause of renal allograft primary nonfunction. |
| Q84978295 | Evidence-based practice guideline for the treatment of CKD |
| Q33796482 | Exome sequencing and in vitro studies identified podocalyxin as a candidate gene for focal and segmental glomerulosclerosis. |
| Q26744558 | FSGS: Diagnosis and Diagnostic Work-Up |
| Q73740085 | Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group |
| Q46188694 | Focal and segmental glomerulosclerosis in children: a longitudinal assessment. |
| Q73091044 | Focal segmental glomerulosclerosis associated with nephrotic syndrome in cholesterol atheroembolism: clinicopathological correlations |
| Q35574612 | Focal segmental glomerulosclerosis--epidemiology aspects in children and adults |
| Q35686453 | Focal segmental glomerulosclerosis: molecular genetics and targeted therapies |
| Q33527568 | Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group |
| Q37455148 | Frequency and clinicopathological characteristics of variants of primary focal segmental glomerulosclerosis in adults presenting with nephrotic syndrome |
| Q81776040 | Glomerulonephritis |
| Q38972849 | Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis |
| Q41207128 | Idiopathic collapsing focal segmental glomerulosclerosis: a clinicopathologic study |
| Q51010272 | IgA nephropathy histologically resembling focal-segmental glomerulosclerosis: a clinicopathologic study of 18 cases. |
| Q24242266 | Immunosuppressive treatment for focal segmental glomerulosclerosis in adults |
| Q36549261 | Interferon alpha sensitisation induced fatal renal insufficiency in a patient with chronic myeloid leukaemia: case report and review of literature. |
| Q91117906 | MeSsAGe risk score: tool for renal biopsy decision in steroid-dependent nephrotic syndrome |
| Q34331403 | Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes |
| Q37658483 | Novel biomarkers in glomerular disease |
| Q92972249 | Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome |
| Q39331611 | Optimal management of primary focal segmental glomerulosclerosis in adults |
| Q35110886 | Other immunosuppressive agents for focal segmental glomerulosclerosis |
| Q71126176 | Pattern of glomerular disease in Saudi Arabia |
| Q83989293 | Predictive factors of chronic kidney disease in primary focal segmental glomerulosclerosis |
| Q35110883 | Primum non nocere: Should adults with idiopathic FSGS receive steroids? |
| Q57945954 | References |
| Q73423986 | Relationship between lymphocyte and clinical steroid responsiveness in focal segmental glomerulosclerosis |
| Q37251705 | Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? |
| Q36583388 | Renal function and proteinuria after successful immunosuppressive therapies in patients with FSGS. |
| Q48799925 | Renin-angiotensin-aldosterone system inhibitors in pediatric focal segmental glomerulosclerosis |
| Q42954060 | Rethinking First-Line Immunosuppression for Idiopathic FSGS. |
| Q36003095 | Role of Myeloid-Derived Suppressor Cells in Glucocorticoid-Mediated Amelioration of FSGS. |
| Q40974180 | TRPC6 G757D Loss-of-Function Mutation Associates with FSGS. |
| Q36098017 | The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome |
| Q59459573 | The clinical trial imperative |
| Q34863791 | The predictive role of histopathological findings in renal insufficiency and complete remission in a sample of Iranian adults with primary focal segmental glomerulosclerosis |
| Q26752836 | Treatment Strategies of Adult Primary Focal Segmental Glomerulosclerosis: A Systematic Review Focusing on the Last Two Decades |
| Q34734638 | Treatment of nephrotic adults with a supplemented, very low-protein diet |
| Q26828859 | Treatment of primary FSGS in adults |
| Q57049336 | Treatment of steroid-resistant nephrotic syndrome in the genomic era |
| Q36686985 | Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS |
| Q36280174 | Unresolved issues and current concepts in management of primary glomerulonephritis. |
| Q34055958 | Up-regulation of the homophilic adhesion molecule sidekick-1 in podocytes contributes to glomerulosclerosis |
| Q47807294 | Urinary Fibrinogen as a Predictor of Progression of CKD. |
Search more.